Skip to content
Search

Latest Stories

India’s Forex Reserves Move Below $400 Billion Mark for First Time in 2018

India’s foreign exchange reserve fell by $819.5 million to $399.282 billion for the week to September 7 falling below the $ 400bn mark for the first time in over 12 months, according to the data released by India’s central bank, Reserve Bank of India (RBI) on Friday (14).

This is the second straight week of a significant decline in the reserves which showcase that central bank has been selling US currency to fight against depreciation of rupee which moved up 73 mark this week to close at 71.84 against the dollar on Friday (14). The total reserves fell by $1.191bn to $400.101bn in the previous week.


In the week to September 7, India’s foreign currency assets, an important component of the overall reserves, recorded a fall by $887.4m to $375.09bn.

India’s foreign currency assets expressed in dollar terms consist the effect of appreciation, depreciation currencies other than US dollar such as euro, pound, yen held in reserves.

Meanwhile, after showing a steady trend for years, India’s gold reserves rose by $71.9m to $20.234bn in the reporting week, RBI noted.

Also, the special drawing rights of the International Monetary Fund (IMF) fell by $1.5m to $1.476bn. The country's reserve place with the fund also recorded a decline by $2.5m to $2.474bn, India’s central bank added.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less